What is the synthetic biology market actually worth?

How big is the synthetic biology market right now?

The best working estimate for the synthetic biology market today is around $20 billion to $30 billion a year, although the real number depends heavily on what we decide to count.

The latest large market studies cluster surprisingly tightly at the lower end of that range. Fortune Business Insights now estimates $20.47 billion for 2026, after putting the market at $17.09 billion in 2025. Grand View Research arrives at $22.1 billion, up from $18.9 billion in 2025.

Other firms use broader definitions and get closer to $30 billion. That leaves us with a useful first answer: anyone quoting a single synthetic biology market number to one decimal place is giving the category more precision than it really has.

The gap comes from scope. Fortune counts DNA synthesis, peptide and protein synthesis, instruments, consumables and services. Grand View includes enzymes, cloning kits, PCR and next-generation sequencing technologies. Once those businesses enter the calculation, the market gets big quickly.

We would therefore use the low-to-mid-$20 billions as the clearest headline estimate today and keep $20 billion to $30 billion as the sensible range. A much narrower count of revenue that exists specifically because customers are buying synthetic-biology products or engineering services would come out lower.

Estimate	2025 market	2026 market	Definition gives us
Fortune Business Insights	$17.09B	$20.47B	Broad commercial market
Grand View Research	$18.9B	$22.1B	Broad tools, technologies and applications
Global Market Insights	About $25.6B	About $30.1B	Larger industrial and tools footprint
The Business Research Company	About $26.6B	About $32B	One of the broadest definitions
Synthetic DNA alone, Grand View	$4.1B	$4.8B	One important submarket
Gene synthesis alone, Fortune	$2.81B	$3.27B	A narrower part of DNA synthesis
Range we would actually use	-	$20B-$30B	Best broad-market estimate today

If you want more recent data on this point, please see our latest synthetic biology market report.

Why do synthetic biology market estimates vary so much?

Synthetic biology market estimates vary so much because researchers are often measuring different businesses under the same name.

Synthetic biology is more like a technology layer than a neat product category. A company can sell DNA, enzymes, laboratory equipment, cell-engineering services, fermentation technology or therapeutics and still sit somewhere inside the synthetic biology ecosystem.

Grand View's latest definition shows how wide that boundary can become. Its market includes PCR, next-generation sequencing, enzymes and cloning technologies. Fortune's study includes synthesis products, laboratory instruments, consumables and services.

Those products certainly help people engineer biology. Counting all of their revenue as synthetic biology revenue is a much stronger assumption.

Take synthetic DNA. Grand View estimates that market alone at $4.8 billion today. Fortune separately estimates gene synthesis at $3.27 billion. Both categories sit inside, or overlap heavily with, broader synthetic biology estimates.

The same issue appears with enzymes and sequencing. Thermo Fisher or Merck can sell a reagent to a synthetic biology lab and to a conventional molecular biology lab. The product is identical, while the market label changes depending on the customer's experiment.

That is why the boundary matters more than whether one report says $20.5 billion and another says $22.1 billion. The definition can move the answer by billions before anybody even starts forecasting growth.

Is synthetic DNA already a big business?

Yes. Synthetic DNA is already a multibillion-dollar market, and it gives us one of the cleanest pieces of evidence that synthetic biology has moved well beyond experimental science.

Grand View currently puts synthetic DNA at $4.8 billion, up from $4.1 billion in 2025. Fortune's narrower gene-synthesis estimate reaches $3.27 billion.

Those numbers line up with what individual suppliers are seeing.

GenScript's life-science products and services business generated $522.1 million in 2025, up 14.8%. The company specifically pointed to demand for AI-driven drug development and gene-to-protein workflows as part of that growth.

Twist Bioscience gives us an even more direct read on synthetic DNA demand. The company manufactures genes, oligos, antibody libraries and other DNA products on its silicon-based platform. Its business has kept expanding, and Twist recently raised $300 million in fresh equity after another strong year of demand.

The company's latest moves also show where DNA synthesis is heading. Twist has expanded its ability to make longer and more complex sequences and has joined Lilly's TuneLab effort for antibody drug discovery. Better AI models can suggest more proteins and biological designs, but researchers still have to manufacture and test those designs. That creates physical demand for companies such as Twist and GenScript.

So AI is already feeding into synthetic biology revenue in a fairly practical way: more computational designs mean more DNA, proteins and experiments to build.

Are synthetic biology companies actually making billions in revenue?

Most of the companies that people instinctively call synthetic biology companies are still far from billion-dollar annual revenue.

That gap is one of the best checks we have on the giant market estimates.

Ginkgo Bioworks generated $170 million in 2025. Its Cell Engineering business contributed $133 million before the company sold its Biosecurity operation and shifted more of its attention toward autonomous laboratories.

Twist generated $376.6 million in fiscal 2025, with $145 million previously classified as synthetic biology revenue.

Codexis, which develops engineered enzymes, produced roughly $70 million in annual revenue. LanzaTech, one of the most visible companies trying to make fuels and chemicals from waste carbon, generated around $56 million.

GenScript's dedicated industrial synthetic biology division reached $58 million in 2025. Its much larger life-science business generated $522 million, although only part of that revenue should be attributed to synthetic biology.

Put several recognizable names together and we still reach only a fraction of the $20 billion-plus headline market.

The missing revenue sits partly inside giant diversified suppliers such as Thermo Fisher, Merck, Eurofins and Novonesis, where synthetic biology sales are difficult to isolate. Private companies add more. Even after allowing for that, the exercise tells us something useful: today's pure-play synthetic biology industry is much smaller than the broad ecosystem sold in market reports.

Company or business	Latest annual revenue reference	How directly it maps to synthetic biology
Twist Bioscience	$376.6M	Strong direct exposure
Ginkgo Bioworks	$170M	Strong direct exposure
Codexis	About $70M	Strong enzyme-engineering exposure
LanzaTech	About $56M	Strong industrial-biology exposure
GenScript Bestzyme	$58M	Dedicated industrial synthetic biology
GenScript Life Science Group	$522.1M	Large but broader than synthetic biology
Large diversified suppliers	Billions overall	Relevant synthetic biology revenue usually undisclosed

If you want more recent data on this point, please see our latest synthetic biology market report.

What happened to Ginkgo Bioworks?

Ginkgo Bioworks currently shows how hard it has been to turn a huge synthetic biology platform story into equally huge revenue.

The latest numbers are unusually stark. Ginkgo reported just $20 million of revenue in its latest quarter, down 48% from $39 million a year earlier. The previous quarter was similar: $19 million, down 49% on the reported comparison.

Some of that decline comes from deliberate restructuring and the cancellation or rationalization of programs. Still, the trajectory is hard to miss.

Annual revenue had already fallen from $251 million in 2023 to $227 million in 2024 and then $170 million in 2025. Cell Engineering revenue dropped from $174 million in 2024 to $133 million in 2025.

Ginkgo is now concentrating heavily on autonomous laboratories. The company launched its cloud-lab offering, has been expanding its Nebula facility and recently won government-linked projects involving autonomous labs at major U.S. universities.

That strategy could open a different business than the original horizontal cell-programming model. For our market-size question, Ginkgo is useful precisely because the company spent years trying to turn "biology is programmable" into a very large general-purpose platform.

The science progressed faster than the revenue model.

Did investors overestimate synthetic biology during the boom?

Yes. Investors clearly priced some synthetic biology companies as though commercial scale would follow technical progress much faster than it actually did.

Zymergen is still the clearest case.

The company reached the public market at roughly a $3 billion valuation. Ginkgo later agreed to acquire it in a deal initially valued around $300 million. Zymergen subsequently entered Chapter 11, and Ginkgo eventually acquired substantially all of its remaining assets for a $6.2 million cash purchase price alongside lease and employment obligations.

Amyris tells a similar story from a different angle.

Amyris engineered microorganisms that could make commercially useful molecules, so the technology did produce real products. The company then tried to build a much larger consumer business around those capabilities and ran into severe financial trouble.

Amyris entered Chapter 11 and sold Biossance for $20 million and MenoLabs for $3 million.

Neither failure erased the underlying biology. They exposed how quickly a technically impressive platform can destroy capital when manufacturing costs, product economics and corporate spending move in the wrong direction.

That correction still shapes synthetic biology today. Investors are asking much harder questions about revenue, margins and manufacturing economics than they did during the previous funding cycle.

If you want more recent data on this point, please see our latest synthetic biology market report.

Is industrial synthetic biology actually working at commercial scale?

Industrial synthetic biology works commercially in selected markets today, but large-scale success is still concentrated in applications where biology has a clear economic advantage.

Novonesis gives us the strongest proof. The combination of Novozymes and Chr. Hansen created a biosolutions company operating at a scale that most synthetic biology startups have never approached. Its enzymes and microorganisms are already used across food, agriculture, household care and industrial production.

GenScript offers a smaller and cleaner pure synthetic biology example. Its Bestzyme industrial synthetic biology business generated $58 million in 2025, up 7.9%.

Codexis has also built a real business around engineered enzymes. LanzaTech sells products made through biological carbon conversion and grew its revenue to roughly $56 million in 2025.

Commercial demand clearly exists.

Profitability is harder. LanzaTech was still losing substantial amounts of money while growing revenue. Codexis has also spent years trying to convert technical capabilities into consistently attractive economics.

The applications that work best tend to have enough value per kilogram to absorb expensive biological manufacturing. Enzymes, specialty ingredients and pharmaceutical inputs can clear that bar more easily than cheap bulk chemicals.

This is where industrial synthetic biology currently looks strongest: targeted products with a clear performance or cost advantage, rather than sweeping replacement of petrochemical manufacturing.

Why is synthetic biology so difficult to scale?

Synthetic biology becomes a manufacturing business once a promising biological design leaves the lab, and manufacturing is where many projects become painfully expensive.

A microorganism can perform beautifully in a small fermenter and disappoint badly at industrial scale. Yield can fall. Fermentation can take too long. Contamination can ruin a batch. Feedstock costs can move. Purification can become more expensive than expected.

The selling price then decides whether any of that is tolerable.

A pharmaceutical ingredient worth thousands of dollars per gram has room for complicated production. A commodity chemical selling for a few dollars per kilogram does not.

This is why we should be careful whenever someone moves directly from "we can engineer an organism to produce this molecule" to a huge addressable-market number. Technical feasibility gets the product into the race. Unit economics decide whether it has a business.

The history of Amyris, Zymergen and several fermentation startups has made that distinction much harder for investors to ignore these days.

Is healthcare quietly becoming the biggest synthetic biology market?

Healthcare is currently one of the strongest commercial markets for synthetic biology because drug development can pay much more for better biological performance than commodity industries can.

Grand View says healthcare is now the largest application inside its synthetic biology market. Biotechnology and pharmaceutical companies account for 54.7% of end-user revenue in its latest study.

The reason is straightforward. Synthetic DNA, engineered proteins, genome editing and cell engineering all feed directly into drug discovery and advanced therapeutics.

GenScript's numbers reinforce that picture. Its life-science business grew 14.8% in 2025, helped in part by stronger demand for gene-to-protein services and AI-driven drug development. ProBio, its biologics development and manufacturing operation, grew even faster, although counting all of that revenue as synthetic biology would stretch the definition too far.

Healthcare also helps explain why North America dominates most current market estimates. Fortune puts North America at $10.57 billion today, including $9.94 billion for the U.S. alone. Grand View uses a narrower regional share of 42.1%, but still places North America comfortably first.

The money follows the concentration of pharmaceutical R&D, biotechnology companies, research institutions and life-science suppliers.

For synthetic biology, healthcare currently offers something industrial commodity markets often cannot: enough economic value per successful product to pay for expensive engineering.

Are investors coming back to synthetic biology?

Investors are putting serious money into synthetic biology again, although the recovery is much more selective than the boom years made it look.

SynBioBeta's broad industry dataset recorded $12.2 billion of investment in 2024, up from $10.7 billion in 2023 after the sharp slowdown that followed the 2021 peak.

That headline needs context because SynBioBeta tracks more than 900 companies across a broad synthetic biology universe. Narrower definitions produce far smaller totals.

The quality of capital also looks different now. Large rounds still happen, but companies increasingly need a clear therapeutic program, platform advantage or commercial product story.

Twist's recent $300 million public offering is a useful example. The company has a physical product customers already buy, rising demand across several research markets and a clear role in the growing AI-biology workflow.

That is a very different funding case from giving hundreds of millions to a company because an engineered organism might eventually disrupt a gigantic commodity market.

Capital has returned, but the bar has moved.

Could synthetic biology become a $100 billion market?

A $100 billion synthetic biology market is plausible in the next decade, although reaching it would require years of very fast growth from a base that is still only around the low-to-mid-$20 billions.

Fortune currently projects $95 billion by 2034. Global Market Insights puts the market at roughly $128 billion by 2035. Grand View is more conservative at about $69 billion by 2033.

These forecasts sound wildly different, yet all three require a similar underlying story: DNA synthesis keeps growing, healthcare applications broaden, engineered enzymes win more industrial work and biological design becomes cheaper and faster.

The mathematics becomes demanding quickly.

A market growing around 20% a year roughly quadruples within eight years. Once annual revenue reaches $40 billion or $50 billion, maintaining that growth requires billions of dollars of fresh business every year.

Synthetic DNA looks capable of supporting part of that expansion. Grand View expects its $4.8 billion market to reach $14.2 billion by 2033. Fortune expects gene synthesis alone to grow from $3.27 billion to almost $11 billion by 2034.

Healthcare can add considerably more. Industrial biotechnology remains the bigger uncertainty because manufacturing economics improve much less predictably.

So $100 billion belongs in the credible upside range for the next decade. Treating it as today's market would be several years ahead of the evidence.

If you want more recent data on this point, please see our latest synthetic biology market report.

Is synthetic biology worth more than the market-size reports suggest?

Synthetic biology probably influences far more economic activity than the $20 billion to $30 billion market figure captures, because the technology sits inside much larger industries.

A synthetic biology tool can help create a drug worth billions of dollars. An engineered enzyme can improve a manufacturing process whose final products generate billions more. A fermentation strain can change how a chemical is produced without the strain developer collecting the full selling price of that chemical.

This is where "market size" starts becoming misleading.

Fortune's latest biotechnology estimate puts the entire biotech market at nearly $1.5 trillion. Synthetic biology will increasingly touch pieces of that enormous base, along with agriculture, chemicals, food and materials.

Counting every downstream dollar would inflate the answer beyond usefulness.

The cleaner way to think about it is economic reach versus supplier revenue. Synthetic biology's economic reach could eventually stretch across trillion-dollar industries. The companies selling DNA, enzymes, engineering services and biological manufacturing capture only part of that value.

That gap is likely to get larger as the technology spreads.

So what is the synthetic biology market actually worth today?

The synthetic biology market is worth roughly $20 billion to $30 billion today, and we would use the low-to-mid-$20 billions as the most defensible single estimate.

The latest published numbers support that range. Fortune is at $20.47 billion and Grand View at $22.1 billion, while broader studies push closer to $30 billion.

Company revenue gives us the necessary reality check. Synthetic DNA already generates several billion dollars. GenScript's life-science business exceeds $500 million. Twist has built a business worth hundreds of millions in annual sales. Large biosolutions companies show that engineered biology can work at industrial scale.

At the same time, Ginkgo's latest quarterly revenue has dropped to $20 million, LanzaTech remains economically difficult despite real product sales, and the collapses of Zymergen and Amyris still show what happens when commercial expectations run years ahead of the business.

The most useful number is therefore around $20 billion to $30 billion for the broad market we can see and sell into today.

A stricter count focused on revenue uniquely attributable to synthetic biology would probably sit below that range. The technology's eventual economic reach could be many times larger, especially as AI increases the number of biological designs researchers can create and test.

For now, the market is already substantial, growing quickly and commercially real. Calling it a $100 billion industry today would still be getting ahead of the money actually changing hands.

If you want more recent data on this point, please see our latest synthetic biology market report.